Pulmatrix Inc. (PULM)

1.06
0.00 (0.00)
NASDAQ : Health Technology
Prev Close 1.06
Open 1.09
Day Low/High 1.04 / 1.09
52 Wk Low/High 0.72 / 6.88
Volume 505.89K
Avg Volume 1.97M
Exchange NASDAQ
Shares Outstanding 18.29M
Market Cap 11.57M
EPS -5.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Pulmatrix And Cipla Technologies LLC Enter Into Definitive Agreement For The Development And Commercialization Of Pulmazole™

Pulmatrix And Cipla Technologies LLC Enter Into Definitive Agreement For The Development And Commercialization Of Pulmazole™

- Transaction marks Cipla's entry into specialty respiratory segment, building on inroads made into the specialty business in the recent past

Pulmatrix, Inc. Announces Closing Of $16.6 Million Upsized Public Offering

Pulmatrix, Inc. Announces Closing Of $16.6 Million Upsized Public Offering

Underwriter Exercises In Full Option to Purchase Additional Securities

Pulmatrix, Inc. Announces Pricing Of $14.4 Million Upsized Public Offering

Pulmatrix, Inc. Announces Pricing Of $14.4 Million Upsized Public Offering

LEXINGTON, Mass., April 3, 2019 /PRNewswire/ -- Pulmatrix, Inc.

Pulmatrix Enters Into Binding Term Sheet With Cipla Technologies LLC For The Development And Commercialization Of Pulmazole

Pulmatrix Enters Into Binding Term Sheet With Cipla Technologies LLC For The Development And Commercialization Of Pulmazole

The Binding Term Sheet Executed on April 1, 2019 Lays Groundwork for Entry into a Definitive Agreement During the 2nd Quarter of 2019

Pulmatrix To Participate In Upcoming Investor Conferences

Pulmatrix To Participate In Upcoming Investor Conferences

LEXINGTON, Mass., March 14, 2019 /PRNewswire/ -- Pulmatrix, Inc.

Pulmatrix Regains NASDAQ Compliance

Pulmatrix Regains NASDAQ Compliance

LEXINGTON, Mass., March 12, 2019 /PRNewswire/ --  Pulmatrix, Inc.

Pulmatrix Receives Five Patents Supporting Claims For Their Novel Inhaled Narrow Spectrum Kinase Inhibitor Programs

Pulmatrix Receives Five Patents Supporting Claims For Their Novel Inhaled Narrow Spectrum Kinase Inhibitor Programs

PUR1800 (1 US Patent) and PUR5700 (2 US Patents and 2 EU Patents) Intellectual Property Portfolio Expands Significantly

Pulmatrix Receives IND Approval For Pulmazole Phase 2 Clinical Study

Pulmatrix Receives IND Approval For Pulmazole Phase 2 Clinical Study

Pulmatrix notified of FDA's authorization to proceed for a Phase 2 study of Pulmazole (inhaled itraconazole) in asthmatic patients with allergic bronchopulmonary aspergillosis (ABPA)

Pulmatrix, Inc. Announces Termination Of Planned Offering Pursuant To Registration Statement On Form S-1

Pulmatrix, Inc. Announces Termination Of Planned Offering Pursuant To Registration Statement On Form S-1

Files Withdrawal of Registration Statement with the SEC

Pulmatrix, Inc. Announces 1-for-10 Reverse Stock Split

Pulmatrix, Inc. Announces 1-for-10 Reverse Stock Split

LEXINGTON, Mass., Feb.

Pulmatrix, Inc. Announces Closing Of Public Offering Of Common Stock

Pulmatrix, Inc. Announces Closing Of Public Offering Of Common Stock

LEXINGTON, Mass., Feb.

Pulmatrix, Inc. Announces Closing Of Public Offering Of Common Stock

Pulmatrix, Inc. Announces Closing Of Public Offering Of Common Stock

LEXINGTON, Mass., Jan.

Pulmatrix, Inc. Announces Pricing Of Public Offering Of Common Stock

Pulmatrix, Inc. Announces Pricing Of Public Offering Of Common Stock

LEXINGTON, Mass., Jan.

Pulmatrix, Inc. Announces Proposed Public Offering Of Common Stock

Pulmatrix, Inc. Announces Proposed Public Offering Of Common Stock

LEXINGTON, Mass., Jan.

Pulmatrix, Inc. Announces Pricing Of Public Offering Of Common Stock

Pulmatrix, Inc. Announces Pricing Of Public Offering Of Common Stock

LEXINGTON, Mass., Jan.

Pulmatrix, Inc. Announces Proposed Public Offering Of Common Stock

Pulmatrix, Inc. Announces Proposed Public Offering Of Common Stock

LEXINGTON, Mass., Jan.

Pulmatrix Announces $3.0 Million Registered Direct Offering

Pulmatrix Announces $3.0 Million Registered Direct Offering

LEXINGTON, Mass., Nov.

Biotech Premarket Movers: PharmAthene, Earth Science Tech, Pulmatrix

Biotech Premarket Movers: PharmAthene, Earth Science Tech, Pulmatrix

PharmAthene shares spiked premarket Tuesday premarket, adding to the massive gains seen a day earlier.

Hopes for Tax Reform, Less Regulation Lift Indices

Hopes for Tax Reform, Less Regulation Lift Indices

Technical indicators indicate the markets are not extended and have consolidated nicely.

These 5 Stocks Under $10 Could Light Up Soon

These 5 Stocks Under $10 Could Light Up Soon

Here's a technical look at how to trade several under $10 stocks that could trigger big breakout trades soon.

Shark Bites: Fed? What Fed?

Shark Bites: Fed? What Fed?

Central bank does nothing on rates; market doesn't do much, period.

These 5 Stocks Under $10 Could Get Hot Soon

These 5 Stocks Under $10 Could Get Hot Soon

Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: APT, BRKS, CXDC, IGLD, PHG, SSFN Downgrades: CLRO, HSNI, HURC, INOV, INUV, MET, SHEN, SOL, SVA Initiations: PULM Read on to get TheStreet Quant Ratings' detailed report:

5 Stocks Under $10 to Trade for Big Breakouts

5 Stocks Under $10 to Trade for Big Breakouts

These stocks trading for less than $10 a share are within range of triggering breakout trades and moving much higher from current levels.